Clik here to view.
HEX Innovation Ltd.与菲律宾UPHDMC签署合作协议
香港 (美国商业资讯)–专业从事区块链医疗平台的HEX Innovation Ltd.（首席执行官Sammy Kwok）面向菲律宾卫生部以及菲律宾主要医院举行了宣讲会。HEX在此期间取得的成就包括与UPHDMC (University of Perpetual Help Dalta Medical Center)签署了一项协议。 HEX Innovation首席营销官Alexander...
View ArticleClik here to view.
Takeda and the New York Academy of Sciences Announce 2019 Innovators in...
NEW YORK & OSAKA, Japan Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science...
View ArticleClik here to view.
武田薬品とニューヨーク科学アカデミーによる”2019 Innovators in Science Award”の受賞者発表について
NEW YORK & OSAKA, Japan （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とニューヨーク科学アカデミー（The New York Academy of Sciences、本部：米国ニューヨーク州ニューヨーク、以下「NYAS」）は、このたび、今年で2回目となる学術賞“Innovators in Science...
View ArticleClik here to view.
武田和纽约科学院宣布2019年度科学创新者奖获奖人
纽约市和日本大阪 (美国商业资讯) — 武田药品工业株式会社（Takeda Pharmaceutical Company Limited，简称“武田”）(TSE:4502)和纽约科学院今天宣布了每年一次的科学创新者奖第二年的获奖人，以表彰他们在再生医学领域的承诺和卓越贡献。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
View ArticleClik here to view.
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleClik here to view.
Aptorum Group Limited Announces Closing of Initial Public Offering
HONG KONG Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic...
View ArticleClik here to view.
Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in...
HONG KONG Aptorum Group Limited (“APM”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic...
View ArticleClik here to view.
武田薬品、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者を治療するためのアドセトリス（ブレンツキシマブ・ベドチン）とAVDの併用に関するCHMPの...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE:...
View ArticleClik here to view.
武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)采纳了一项肯定意见，延长ADCETRIS (brentuximab vedotin)的上市许可，并推荐核准该药联合AVD用于既往未曾治疗的CD30+...
View ArticleClik here to view.
Spirita Oncology Initiated Global Clinical Development of E6201 in...
BOSTON Spirita Oncology, LLC, announced that it has entered into a sublicense agreement with JS Innopharm (Shanghai) Ltd. to initiate global clinical development of E6201, a potent MEK1 inhibitor...
View ArticleClik here to view.
クック ジャパン 新代表取締役就任のお知らせ
東京都中野区 （ビジネスワイヤ） — Cook Japan株式会社（本社：東京都中野区、以下「クック ジャパン」）は、このほどバリー・トーマス（Barry Thomas）が新たに代表取締役に就任したことを発表いたします。トーマスは、2001年にクック...
View ArticleClik here to view.
Macrogen Becomes the First Clinical Lab in Korea to Receive CLIA Accreditation
SEOUL, South Korea The precision medicine and biotechnology company, Macrogen (CEO Kap-Seok Yang, www.macrogen.com) (KOSDAQ: 038290), announced on December 20 that its NGS clinical laboratories in...
View ArticleClik here to view.
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES...
TOKYO & NEW YORK Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating...
View ArticleClik here to view.
Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad...
MONT-SAINT-GUIBERT, Belgium & TOKYO Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced a strategic investment of EUR10 million by ITOCHU...
View ArticleClik here to view.
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360®...
ST. PAUL, Minn. Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral...
View ArticleClik here to view.
1ST Biotherapeutics and twoXAR Form Co-Development Collaboration to Discover...
SEONGNAM, South Korea & MOUNTAIN VIEW, Calif. 1ST Biotherapeutics, Inc., a preclinical-stage biotechnology company focused on neurodegenerative diseases, immuno-oncology, and orphan diseases,...
View ArticleClik here to view.
Takeda Announces Multiple Cell Therapy Collaborations to Advance the...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus...
View ArticleClik here to view.
Harbour BioMed Appoints Atul Deshpande, Ph.D. MBA, Chief Strategy Officer and...
SHANGHAI & CAMBRIDGE, Mass. & ROTTERDAM, Netherlands Harbour BioMed announced the appointment of Atul Deshpande, Ph.D. MBA, as Chief Strategy Officer and Head of U.S. Operations. Dr....
View ArticleClik here to view.
武田宣布多项细胞疗法合作，以推进公司的新型免疫肿瘤学阵容
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社（“武田”）(TSE: 4502)今天宣布新的免疫肿瘤学(I-O)研究合作，这是该公司关键战略重点领域。通过上述合作，武田寻求加快发现下一代癌症免疫治疗药物，包括新型细胞疗法，该方法有望为满足难治性癌症患者需求提供重要机遇。 武田肿瘤治疗领域部主管Phil Rowlands,...
View Article